Core Insights - Iovance Biotherapeutics reported a narrower loss per share of 18 cents for Q4 2025, compared to a loss of 22 cents expected by analysts, and a loss of 26 cents in the same quarter last year [2] - Total revenues for Q4 2025 reached $87 million, a 17.6% increase year-over-year, surpassing the Zacks Consensus Estimate of $75 million [2] - For the full year 2025, Iovance achieved total revenues of approximately $264 million, reflecting a 61% year-over-year increase, and a net loss per share of $1.09, improved from a loss of $1.28 in 2024 [5] Revenue Breakdown - Amtagvi sales contributed approximately $65 million in Q4 2025, marking a 33.4% year-over-year increase, exceeding the Zacks Consensus Estimate of $61 million [3] - Proleukin generated $22 million in Q4 2025, down 12% year-over-year, but still beating the Zacks Consensus Estimate of $15 million [3] Cost Management - Research and development expenses for Q4 2025 totaled $71.2 million, a slight increase of 0.3% from the previous year [3] - Selling, general, and administrative expenses decreased by 14% year-over-year to $36.4 million, attributed to lower stock compensation expenses [4] - The company reported a gross margin of 50% in Q4 2025, up from 43% in the previous quarter, due to improved operational efficiency [4] Market Position and Outlook - Estimates for Iovance have been trending upward, with a 22.73% shift in consensus estimates over the past month [6] - The company holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [8] - Iovance Biotherapeutics has a Growth Score of B and a Momentum Score of A, but a low Value Score of F, placing it in the bottom 20% for value investment strategy [7] Industry Comparison - Iovance operates within the Zacks Medical - Biomedical and Genetics industry, where Amicus Therapeutics reported revenues of $185.21 million for the last quarter, a year-over-year increase of 23.7% [9][10] - Amicus Therapeutics has a Zacks Rank 3 (Hold) and a VGM Score of C, similar to Iovance [11]

Iovance Biotherapeutics Conference Call Summary Company Overview - **Company**: Iovance Biotherapeutics (NasdaqGM: IOVA) - **Industry**: Biotechnology, specifically focused on cancer immunotherapy Key Points Financial Performance - **2025 Revenue**: Approximately $264 million, within annual guidance range, with a 30% quarterly revenue growth in Q4 driven by AMTAGVI [4][5] - **Gross Margin**: Achieved a record 50% gross margin from cost of sales in Q4 2025 [4][6] - **Cash Runway**: Extended into Q3 2027 due to ongoing cost-saving initiatives [13] Product Launch and Market Opportunity - **AMTAGVI**: First approved therapy for previously treated advanced melanoma, with a market opportunity exceeding $1 billion in the U.S. [5] - **Proleukin**: Significant sales in Q4, primarily used in conjunction with AMTAGVI; accounted for 17% of total revenue in the previous year [23][24] - **Demand Dynamics**: Positive uptake of AMTAGVI, with increasing enrollment volumes from authorized treatment centers (ATCs) [6][8] Clinical Data and Pipeline - **Durability Data**: 5-year clinical data shows a 31% response rate and near 20% median overall survival in heavily pretreated patients [7] - **New Indications**: Plans to expand TIL therapy into non-small cell lung cancer and aggressive soft tissue sarcomas, with promising early data showing a 50% confirmed response rate in sarcomas [10][11][50] - **Regulatory Designations**: Fast Track designation granted by the FDA for lifileucel in non-small cell lung cancer [10][48] Operational Excellence - **Manufacturing Control**: All manufacturing for AMTAGVI is conducted in-house at the Iovance Cell Therapy Center (ICTC), allowing for better operational efficiency and cost control [19][20] - **Continuous Improvement**: Focus on enhancing manufacturing processes and operational efficiencies to improve margins [21][22] Future Growth Strategy - **Three Core Pillars**: 1. Accelerate U.S. commercial launch of AMTAGVI 2. Expand TIL pipeline into new indications and next-generation products 3. Optimize operational excellence to extend cash runway and drive profitability [5][12] - **Community Engagement**: Initiatives to deepen penetration within existing ATCs and expand into community treatment centers [32][34] Investor Insights - **Underappreciated Aspects**: The importance of patient outcomes and the company's manufacturing capabilities are highlighted as key factors that investors may overlook [59][60] - **Future of TIL Therapy**: Positioned as a leader in TIL therapy, with potential for scalability and expansion into various solid tumor indications [60][62] Guidance and Market Considerations - **Revenue Guidance**: Future guidance to be provided once more data points are available, with expectations of continued momentum from Q4 into 2026 [25][31] - **Market Competition**: The company does not anticipate significant impact from competitors like Replimune, as they target different patient populations [26] This summary encapsulates the critical insights from the Iovance Biotherapeutics conference call, focusing on financial performance, product development, operational strategies, and future growth opportunities.

Core Insights - Iovance Biotherapeutics reported a narrower loss of 18 cents per share for Q4 2025, compared to a loss of 26 cents in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 22 cents [1][6] - Total revenues for Q4 increased by 17.6% year over year to $87 million, surpassing the Zacks Consensus Estimate of $75 million [1][6] Revenue Breakdown - Iovance has two marketed drugs: Proleukin and Amtagvi. Proleukin generated $22 million in Q4, down 12% year over year, while Amtagvi sales reached approximately $65 million, a 33.4% increase year over year, exceeding the Zacks Consensus Estimate of $61 million [2][3] Operating Costs - Research and development expenses were $71.2 million in Q4, a slight increase of 0.3% from the previous year. Selling, general, and administrative expenses decreased by 14% to $36.4 million due to lower stock compensation expenses [4] Financial Position - Iovance reported a gross margin of 50% in Q4, up from 43% in the previous quarter, attributed to improved operational efficiency following a restructuring plan [5] - As of December 31, 2025, the company had cash and investments totaling $303 million, down from $307 million as of September 30, 2025, with expectations to fund operations into Q3 2027 [5] Full-Year Performance - For the full year 2025, Iovance reported total revenues of approximately $264 million, a 61% increase year over year, and a net loss per share of $1.09, an improvement from a loss of $1.28 per share in 2024 [6] Pipeline Developments - Iovance announced positive early-stage study results for Amtagvi in advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), with an objective response rate (ORR) of 50% [7][9] - The company plans to initiate a registrational study for Amtagvi in second-line advanced UPS and DDLPS in Q2 2026 and is engaging with the FDA regarding a potential regulatory pathway [9] Market Response - Following the announcement of Q4 results and positive study data, Iovance shares rose by 31%. However, the stock has declined by 29.2% over the past year, contrasting with the industry's growth of 18.8% [10]

Core Viewpoint - Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the commercialization of their products, with Iovance specializing in cancer immunotherapies and Rigel in hematologic disorders and cancer. The analysis aims to determine which company presents a better investment opportunity today. Summary of Iovance Biotherapeutics (IOVA) - Iovance has two marketed products: Proleukin for metastatic renal cell carcinoma and metastatic melanoma, and Amtagvi, the first FDA-approved individualized cell therapy for melanoma patients [2][3] - Amtagvi is expected to generate significant revenue, with projected sales of $155.1 million in the first nine months of 2025, reflecting a 183% year-over-year increase [3] - Total product revenues for Iovance are anticipated to be between $250 million and $300 million for the full year 2025, primarily driven by Amtagvi [4] - The company is exploring label expansions for Amtagvi in various cancer types, including cervical cancer and non-small cell lung cancer (NSCLC), with regulatory filings expected [5][6] - Iovance faced challenges in 2025, including a revenue guidance cut from $450-$475 million to $250-$300 million and the withdrawal of its EU filing for Amtagvi due to regulatory misalignment [7] Summary of Rigel Pharmaceuticals (RIGL) - Rigel has shown strong performance in 2025, with sales rising 60% to $232 million, primarily driven by Tavalisse, which generated nearly $159 million [8][10][11] - Tavalisse is approved for treating adults with low platelet counts due to chronic immune thrombocytopenia, and its strong demand has reinforced Rigel's revenue base [9][11] - Rigel's oncology assets, including Gavreto and Rezlidhia, contributed additional revenue, with Gavreto generating about $42 million and Rezlidhia $31 million [12] - The company projects 2026 net product sales of $255-$265 million and expects to achieve positive net income while funding clinical development programs [13] - Rigel faces competition from larger pharmaceutical companies, notably Sanofi's Wayrilz, which poses a threat to Tavalisse [15] Financial Estimates and Performance - The Zacks Consensus Estimate for IOVA's 2026 sales is expected to grow by over 81%, with loss estimates per share improving by 34% [17] - For Rigel, the 2026 sales estimate is expected to decline by 3%, with EPS estimates dropping by about 41% [18] - In the past year, IOVA shares have decreased by 46%, while RIGL shares have increased by 59%, contrasting with an industry growth of nearly 18% [19] - Iovance is trading at a premium with a price/sales ratio of 4.20, compared to Rigel's 2.33 [21] Investment Considerations - Both companies hold a Zacks Rank 3 (Hold), complicating the investment decision [23] - Iovance is viewed as a safer investment due to its growth potential from Amtagvi and ongoing pipeline programs, despite its premium valuation [24] - Rigel, while operationally stronger in the short term, has a more concentrated portfolio and faces increasing competition [24] - Iovance's past setbacks are seen as temporary, with potential for greater upside if commercialization trends stabilize [25]

Financial Data and Key Metrics Changes - Iovance reported a robust 30% revenue growth in Q4 2025, with total revenue for the year reaching approximately $264 million, which is a 61% increase year-over-year [5][15] - The company achieved a gross margin of 50% in Q4, up from 43% in Q3, reflecting operational optimization and improved manufacturing efficiency [15][16] - Cash position at year-end was approximately $303 million, extending the cash runway into Q3 2027 [16] Business Line Data and Key Metrics Changes - Product revenue for Q4 was $87 million, marking a 30% increase from the previous quarter, primarily driven by Amtagvi [15] - Amtagvi revenue grew by 112% year-over-year, contributing significantly to the overall revenue growth [15] - The gross-to-net adjustments for 2025 remained minimal at less than 2% [15] Market Data and Key Metrics Changes - The U.S. market for Amtagvi is projected to exceed $1 billion in peak sales, with significant potential for expansion into non-squamous non-small cell lung cancer, which is seven times larger than the current melanoma opportunity [7][21] - The company is preparing for commercial launch in previously treated non-squamous non-small cell lung cancer, targeting approximately 50,000 addressable patients in the U.S. [21] Company Strategy and Development Direction - Iovance's strategy focuses on three core pillars: accelerating the U.S. commercial launch of Amtagvi, expanding the TIL pipeline into new indications, and enhancing operational excellence [7][12] - The company aims to leverage its TIL platform for new indications, including aggressive soft tissue sarcomas, where it has demonstrated a 50% confirmed response rate in early trials [11][28] - Iovance is committed to maximizing shareholder value and achieving profitability while minimizing dilution [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in remarkable revenue growth for 2026, driven by increased demand for Amtagvi and operational improvements [8][20] - The FDA granted Fast Track designation for lifileucel, validating the clinical trial data and highlighting the unmet medical need in the targeted indications [10][25] - Management emphasized the importance of operational excellence and financial discipline to support future growth and profitability [12][16] Other Important Information - The company has transitioned all lifileucel manufacturing to its U.S.-based Iovance Cell Therapy Center, optimizing internal capacity and reducing costs [24] - Iovance is exploring additional sarcoma subtypes for potential treatment options, addressing a significant unmet medical need in the oncology space [68] Q&A Session Summary Question: Can we expect first-line melanoma data with Amtagvi PD-1 combo data later this year? - Management indicated that an early interim read is possible, but they cannot commit to a specific timeline for 2026 [30][32] Question: Can you elaborate on the quarter-over-quarter jump in Proleukin revenue? - Management noted that the increase was driven by Amtagvi demand, with expectations for further improvement in gross margins [37][38] Question: How has the manufacturing success rate changed over time? - Management stated that manufacturing success is improving, contributing to better margins, but specific percentages are not disclosed [40][44] Question: Why was 2026 guidance not provided now? - Management is ensuring that projections are well-supported before releasing guidance, which is expected soon [48][49] Question: Can you discuss the fourth quarter acceleration from new community ATCs? - Management confirmed significant growth from academic ATCs and expects new community ATCs to ramp up throughout the year [53][54] Question: What are the plans for expanding into other sarcoma subtypes? - Management confirmed interest in exploring additional sarcoma subtypes due to strong activity for TIL therapy in this area [68]

Financial Data and Key Metrics Changes - Iovance reported approximately 30% revenue growth in Q4 2025, with total revenue of about $264 million for the full year, which was a 61% increase over the prior year [5][15] - The company achieved a gross margin of 50% in Q4, up from 43% in Q3, reflecting operational optimization and disciplined capital use [15][16] - Cash position at year-end was approximately $303 million, extending the cash runway into the third quarter of 2027 [16] Business Line Data and Key Metrics Changes - Product revenue for AMTAGVI grew by 112% year-over-year, contributing significantly to the overall revenue growth [15] - Fourth quarter product revenue reached $87 million, marking a 30% increase from the prior quarter, driven by AMTAGVI [15] Market Data and Key Metrics Changes - The U.S. market for AMTAGVI is projected to exceed $1 billion in peak sales, with significant potential for expansion into non-squamous non-small cell lung cancer, which is approximately seven times larger than the current melanoma opportunity [7][21] - The company is preparing for commercial launch in previously treated non-squamous non-small cell lung cancer, targeting around 50,000 addressable patients in the U.S. [21] Company Strategy and Development Direction - Iovance's strategy focuses on three core pillars: accelerating the U.S. commercial launch of AMTAGVI, expanding the TIL pipeline into new indications, and enhancing operational excellence [7][12] - The company aims to leverage its TIL platform for new indications, including aggressive soft tissue sarcomas, which have shown a 50% confirmed response rate in early trials [11][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in remarkable revenue growth for 2026, driven by AMTAGVI and operational improvements [9][20] - The company is focused on maximizing shareholder value and achieving profitability while continuing to innovate in cell therapies for cancer [12][94] Other Important Information - Iovance has received Fast Track designation from the FDA for lifileucel in non-squamous non-small cell lung cancer, validating the clinical trial data [10][25] - The company is also exploring additional sarcoma subtypes for potential treatment options, addressing significant unmet medical needs [68] Q&A Session Summary Question: Update on TILVANCE enrollment and data expectations - Management indicated that early interim read data may be available soon, but cannot commit to specific timelines for 2026 [30][31] Question: Insights on Proleukin revenue and future expectations - Proleukin revenue in Q4 was driven primarily by AMTAGVI demand, with expectations for stabilization moving forward [36][73] Question: Manufacturing success rates and scrap costs - Management noted improvements in manufacturing success rates and indicated that scrap costs would be detailed in the upcoming 10-K filing [39][41] Question: Guidance for 2026 revenue - Management is taking time to ensure projections are well-supported before providing guidance, which is expected soon [47][48] Question: Community ATC setup and differences from academic centers - The learning curve for community ATCs is expected to be similar to that of academic centers, with gradual ramp-up in patient treatment [88]

Financial Data and Key Metrics Changes - Iovance reported a robust 30% revenue growth in 2025, with total revenue reaching approximately $264 million, which was well within the annual guidance range [4][11] - The fourth quarter product revenue was $87 million, reflecting a 30% increase from the prior quarter and a 112% year-over-year growth driven by Amtagvi [11][12] - Gross margin from cost of sales improved to 50% in the fourth quarter, up from 43% in the third quarter, attributed to operational optimization and internalization of manufacturing [12][19] Business Line Data and Key Metrics Changes - Amtagvi's revenue growth was a significant driver, with a 112% increase year-over-year, contributing to the overall revenue growth [11][12] - The company achieved its best-ever gross margin of 50% in the fourth quarter, indicating improved operational efficiency [12][19] - Proleukin revenue also saw a notable increase, with all three distributors ordering in the fourth quarter, although specific future splits were not provided [32][66] Market Data and Key Metrics Changes - The U.S. market for advanced melanoma is expected to see significant growth, with projections indicating potential peak sales of over $1 billion for Amtagvi [5][68] - The non-small cell lung cancer market opportunity is approximately seven times larger than the current melanoma opportunity, with an estimated peak sales potential of $10 billion in the U.S. alone [17][68] - The company is also preparing for commercial launch in previously treated non-squamous non-small cell lung cancer, which represents a substantial market opportunity [17][68] Company Strategy and Development Direction - Iovance plans to focus on three core pillars: accelerating the U.S. commercial launch of Amtagvi, expanding the TIL pipeline into new indications, and enhancing operational excellence [5][6] - The company aims to leverage its TIL platform for broader applications in solid tumors, with a focus on previously treated non-squamous non-small cell lung cancer and aggressive soft tissue sarcomas [6][8] - The operational strategy includes optimizing manufacturing processes and maintaining a strong cash position to support growth initiatives through 2027 [12][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in remarkable revenue growth for 2026, driven by increased demand for Amtagvi and operational improvements [6][11] - The FDA granted Fast Track designation for lifileucel, validating the clinical trial data and highlighting the unmet medical need in the targeted indications [7][20] - Management emphasized the importance of early treatment and the positive real-world data supporting the efficacy of Amtagvi, which is expected to resonate with healthcare professionals [16][85] Other Important Information - The company has extended its cash runway into the third quarter of 2027, supported by ongoing cost-saving initiatives [4][12] - Iovance is actively pursuing approvals in international markets, including Canada, the U.K., Australia, and Switzerland, to expand its global footprint [17][19] Q&A Session Summary Question: Can we expect first-line melanoma data with Amtagvi PD-1 combo data later this year? - Management indicated that an early interim read is possible, but they cannot commit to a specific timeline for 2026 [26][27] Question: Can you elaborate on the quarter-over-quarter jump in Proleukin revenue? - Management noted that all three distributors ordered in Q4, and they expect further improvement in margins moving forward [32][33] Question: How has the manufacturing success rate changed over time? - Management stated that manufacturing success is improving, contributing to better margins, but specific percentages are not disclosed [35][39] Question: Why was 2026 guidance not provided now? - Management is ensuring that projections are well-supported before releasing guidance, which is expected soon [43][44] Question: Can you discuss the fourth quarter acceleration from new community ATCs versus existing academic centers? - Management highlighted significant growth in academic ATCs and expects new community ATCs to ramp up throughout the year [48][49] Question: When might we see the full sarcoma data and at what medical conference? - Management plans to present the data at a major medical congress, with details to be finalized soon [51][52] Question: What is the path to full approval in non-small cell lung cancer? - The Fast Track designation is beneficial, and management is confident about the product's potential benefits for patients [60][61] Question: Are there plans to expand into other subtypes of sarcoma? - Management confirmed interest in exploring additional sarcoma subtypes due to the strong activity observed [62][63]

Core Insights - Iovance Biotherapeutics reported approximately 30% quarterly revenue growth driven by increasing demand for Amtagvi, achieving full year 2025 revenue of $264 million, which met the annual guidance range of $250 million to $300 million [3][4] - The gross margin improved to 50% in the fourth quarter of 2025, reflecting operational improvements and cost optimization [4][3] - The company is well-positioned for future profitability as it advances its registrational trial in non-small cell lung cancer and continues to develop its TIL pipeline [3][4] Financial Performance - Fourth quarter 2025 total product revenue was approximately $87 million, a 30% increase from the previous quarter, with U.S. Amtagvi revenue of about $65 million and global Proleukin revenue of around $22 million [4] - Full year 2025 total product revenue reached approximately $264 million, including U.S. Amtagvi revenue of about $220 million and global Proleukin revenue of approximately $44 million [4] - The cash position as of December 31, 2025, was approximately $303 million, expected to fund operations into the third quarter of 2027 [4] Operational Highlights - The company has implemented operational excellence initiatives, including the internalization of all lifileucel manufacturing, which are expected to drive further improvements in operating expenses and gross margin in 2026 and 2027 [4] - A growing network of U.S. authorized treatment centers (ATCs) has expanded patient access, with community ATCs beginning to treat patients in late 2025 [4][6] - An oral presentation reported an overall objective response rate (ORR) of approximately 44% for Amtagvi, with a higher ORR of 52% after two or fewer prior lines of therapy, emphasizing the importance of early treatment [4][6] Regulatory and Pipeline Developments - The U.S. FDA granted Fast Track Designation for lifileucel in the treatment of advanced non-small cell lung cancer, with positive interim data indicating a potential best-in-class profile [5][6] - Iovance plans to support a supplemental Biologics License Application for U.S. accelerated approval with a potential launch in the second half of 2027 [5][6] - The company is also advancing multiple clinical trials across various solid tumor indications, including a registrational trial for advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma [5][6]

Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Core Insights - Iovance Biotherapeutics Inc. is identified as a promising biotech penny stock, with Barclays raising its price target to $10 from $9 while maintaining an Overweight rating [1] - The company reported a total product revenue of $68 million in Q3 2025, marking a 13% sequential increase, primarily driven by Amtagvi sales of $58 million [2] - Iovance plans to centralize all Amtagvi and clinical manufacturing at its internal facility by early 2026 to enhance capacity and gross margins [3] Financial Performance - Iovance's Q3 2025 product revenue was $68 million, a 13% increase from the previous quarter [2] - The company reaffirmed its full-year 2025 revenue guidance of $250 to $300 million [2] - Management projects peak US sales for Amtagvi in advanced melanoma to exceed $1 billion, supported by over 80 Authorized Treatment Centers across approximately 40 states [2] Strategic Developments - A major operational shift is planned for early 2026, centralizing manufacturing to eliminate reliance on contract manufacturers and maximize capacity [3] - Iovance is pursuing a larger market in non-small cell lung cancer (NSCLC), with interim data from the IOV-LUN-202 trial showing a 26% objective response rate [4] - Enrollment for the IOV-LUN-202 trial is expected to finish in 2026, supporting a potential supplemental BLA and commercial launch in H2 2027 [4] Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumors in the US [5]